BioNet Asia
A private biotech delivering recombinant and mRNA vaccines for respiratory diseases, with an EU‑approved pertussis product.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech delivering recombinant and mRNA vaccines for respiratory diseases, with an EU‑approved pertussis product.
Respiratory Infectious DiseasesVaccines
Technology Platform
Recombinant DNA protein vaccines and mRNA vaccine platforms enabling rapid design of genetically‑engineered antigens for respiratory pathogens.
Opportunities
Leverage EU‑approved pertussis vaccine to enter additional markets and expand mRNA platform for emerging respiratory pathogens.
Risk Factors
Regulatory hurdles, competition from large vaccine manufacturers, and scaling manufacturing capacity.
Competitive Landscape
Competes with GSK, Sanofi, and Pfizer in pertussis vaccines; differentiates through recombinant technology and in‑house GMP manufacturing.